Information Provided By: 
Fly News Breaks for March 14, 2019
GILD
Mar 14, 2019 | 16:15 EDT
BMO Capital analyst Matthew Luchini started Gilead Sciences with an Outperform rating and $78 price target. The company's HIV franchise should remain dominant for at least the next several years while a growing dividend and continued buybacks "provide investors with a baseline return," Luchini tells investors in a research note. Further, the analyst believes current levels provide an attractive entry point.
News For GILD From the Last 2 Days
There are no results for your query GILD
